Fig. 4From: Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world settingThe resistance mechanism clarified by the patient and the frequency of T790M in two groups a EGFR-TKI combined with chemotherapy; b EGFR-TKI monotherapyBack to article page